RU2237063C9 - Полусинтетический способ и новые соединения - Google Patents

Полусинтетический способ и новые соединения Download PDF

Info

Publication number
RU2237063C9
RU2237063C9 RU2001133386/04A RU2001133386A RU2237063C9 RU 2237063 C9 RU2237063 C9 RU 2237063C9 RU 2001133386/04 A RU2001133386/04 A RU 2001133386/04A RU 2001133386 A RU2001133386 A RU 2001133386A RU 2237063 C9 RU2237063 C9 RU 2237063C9
Authority
RU
Russia
Prior art keywords
group
compound
formula
ring
saframycin
Prior art date
Application number
RU2001133386/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2001133386A (ru
RU2237063C2 (ru
Inventor
Кармен КУЭВАС (ES)
Кармен Куэвас
Марта ПЕРЕС (ES)
Марта ПЕРЕС
Андрес ФРАНСЕСЧ (ES)
Андрес ФРАНСЕСЧ
Каролина ФЕРНАНДЕС (ES)
Каролина ФЕРНАНДЕС
Хосе Луис ЧИЧАРРО (ES)
Хосе Луис ЧИЧАРРО
Пилар ГАЛЬЕГО (ES)
Пилар ГАЛЬЕГО
Мари САРСУЭЛО (ES)
Мария САРСУЭЛО
ЛА КАЛЬЕ Фернандо ДЕ (ES)
ЛА КАЛЬЕ Фернандо ДЕ
Игнасио МАНСАНАРЕС (ES)
Игнасио МАНСАНАРЕС
Original Assignee
Фарма Мар, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911345.8A external-priority patent/GB9911345D0/en
Priority claimed from GBGB9918178.6A external-priority patent/GB9918178D0/en
Priority claimed from GBGB9923632.5A external-priority patent/GB9923632D0/en
Priority claimed from GB0001063A external-priority patent/GB0001063D0/en
Application filed by Фарма Мар, С.А. filed Critical Фарма Мар, С.А.
Publication of RU2001133386A publication Critical patent/RU2001133386A/ru
Publication of RU2237063C2 publication Critical patent/RU2237063C2/ru
Application granted granted Critical
Publication of RU2237063C9 publication Critical patent/RU2237063C9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
RU2001133386/04A 1999-05-14 2000-05-15 Полусинтетический способ и новые соединения RU2237063C9 (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB9911345.8 1999-05-14
GBGB9911345.8A GB9911345D0 (cs) 1999-05-14 1999-05-14
GB9918178.6 1999-08-02
GBGB9918178.6A GB9918178D0 (en) 2000-05-15 1999-08-02 Synthetic methods
GBGB9923632.5A GB9923632D0 (en) 1999-10-06 1999-10-06 Hemisynthetic process towards ecteinascidin and phtalscidin compounds
GB9923632.5 1999-10-06
GB0001063.7 2000-01-17
GB0001063A GB0001063D0 (en) 2000-01-17 2000-01-17 Hemisynthetic process towards ecteinascidin and phtalascidin
PCT/GB2000/001852 WO2000069862A2 (en) 1999-05-14 2000-05-15 Hemisynthetic method and intermediates thereof

Publications (3)

Publication Number Publication Date
RU2001133386A RU2001133386A (ru) 2003-06-27
RU2237063C2 RU2237063C2 (ru) 2004-09-27
RU2237063C9 true RU2237063C9 (ru) 2008-10-10

Family

ID=42632476

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001133386/04A RU2237063C9 (ru) 1999-05-14 2000-05-15 Полусинтетический способ и новые соединения

Country Status (29)

Country Link
US (3) US7241892B1 (cs)
EP (1) EP1185536B1 (cs)
JP (1) JP4445136B2 (cs)
KR (1) KR100834601B1 (cs)
CN (3) CN1229382C (cs)
AR (1) AR035842A1 (cs)
AT (1) ATE283273T1 (cs)
AU (2) AU775580B2 (cs)
BG (1) BG65896B1 (cs)
BR (3) BRPI0010559B8 (cs)
CA (2) CA2372058C (cs)
CY (1) CY1108095T1 (cs)
CZ (3) CZ303536B6 (cs)
DE (1) DE60016209T2 (cs)
DK (1) DK1185536T3 (cs)
ES (2) ES2233367T3 (cs)
HU (1) HU230646B1 (cs)
MX (1) MXPA01011631A (cs)
MY (1) MY130271A (cs)
NO (2) NO322016B1 (cs)
NZ (1) NZ515424A (cs)
PL (1) PL226890B1 (cs)
PT (1) PT1185536E (cs)
RU (1) RU2237063C9 (cs)
SI (2) SI1185536T1 (cs)
SK (2) SK287835B6 (cs)
TR (1) TR200103273T2 (cs)
UA (1) UA75333C2 (cs)
WO (3) WO2000069862A2 (cs)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2331593C (en) 1998-05-11 2008-08-05 Pharma Mar, S.A. Metabolites of ecteinascidin 743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
WO2001077115A1 (en) 2000-04-12 2001-10-18 Pharma Mar, S.A. Antitumoral ecteinascidin derivatives
US7919493B2 (en) * 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
NZ521808A (en) * 2000-05-15 2004-07-30 Pharma Mar S Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
WO2002040477A2 (en) 2000-11-03 2002-05-23 President And Fellows Of Harvard College Saframycins, analogues and uses thereof
CZ20031327A3 (cs) * 2000-11-06 2003-11-12 Pharma Mar, S. A. Užití ET-743 k výrobě léků pro účinnou protinádorovou léčbu
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
MXPA04003674A (es) * 2001-10-19 2004-07-23 Pharma Mar Sa Uso mejorado de compuesto antitumoral en terapia de cancer.
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0229793D0 (en) * 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
US7183054B2 (en) 2003-06-03 2007-02-27 President And Fellows Of Harvard College Assay for identifying biological targets of polynucleotide-binding compounds
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
DE602004016376D1 (de) 2003-11-13 2008-10-16 Pharma Mar Sau Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
CN1897949A (zh) * 2003-11-14 2007-01-17 马尔药品公司 包含使用et－743和紫杉醇来治疗癌症的联合疗法
JP2008514688A (ja) * 2004-09-29 2008-05-08 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル 抗炎症剤としてのエクテイナシジン化合物
RU2359700C2 (ru) * 2004-10-26 2009-06-27 Фарма Мар С.А., Сосьедад Униперсональ Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
ATE368461T1 (de) 2004-10-29 2007-08-15 Pharma Mar Sa Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
KR100712667B1 (ko) 2006-04-11 2007-05-02 재단법인서울대학교산학협력재단 신규한 디아자 헤테로고리 유도체 및 그의 고체상 제조방법
GB0708691D0 (en) * 2007-05-04 2007-06-13 Pharma Mar Sa Anticancer treatments a
US20090076017A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched trabectedin
EP2201141A1 (en) * 2007-10-19 2010-06-30 Pharma Mar S.A. Prognostic molecular markers for et-743 treatment
EP2303274A1 (en) * 2008-05-16 2011-04-06 Pharma Mar S.A. Multiple myeloma treatments
US20110070232A1 (en) * 2008-05-16 2011-03-24 Pharma Mar, S.A. Combination Therapy with an Antitumor Alkaloid
WO2011048210A1 (en) 2009-10-22 2011-04-28 Pharma Mar, S.A. PDGFR-α AS RESPONSE MARKER FOR PM00104 TREATMENT
US9428524B2 (en) 2010-05-25 2016-08-30 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds
BR112013011480B1 (pt) 2010-11-12 2022-03-22 Pharma Mar, S.A Uso de pm01183 ou um sal farmaceuticamente aceitável do mesmo e kit para uso no tratamento de câncer
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
CN107739387B (zh) * 2017-10-16 2020-01-03 上海皓元生物医药科技有限公司 一种制备曲贝替定的关键中间体化合物的方法
CN109912629B (zh) * 2017-12-13 2021-12-24 浙江中科创越药业有限公司 天然产物Trabectedin的制备
TWI824043B (zh) 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
CN111518110B (zh) * 2019-02-01 2023-11-03 博瑞生物医药（苏州）股份有限公司 一种海鞘素化合物及其中间体的制备方法
CN111620792B (zh) * 2019-02-28 2023-01-03 兰州大学 一种n,n-二取代氰基甲酰胺的合成方法
CN118924689A (zh) 2019-11-21 2024-11-12 法马马有限公司 用鲁比卡丁制剂治疗小细胞肺癌的方法
CN116217584A (zh) * 2021-12-06 2023-06-06 南通诺泰生物医药技术有限公司 Et743及其中间体的光催化合成方法
EP4651871A2 (en) * 2023-01-17 2025-11-26 Adcytherix SAS Ecteinascidin derivative antibody drug conjugates
WO2025077996A1 (en) 2023-10-09 2025-04-17 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds
WO2025233522A1 (en) 2024-05-10 2025-11-13 Pharma Mar, S.A. Synthetic process for an ecteinascidin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
RU96115394A (ru) * 1995-08-02 1998-12-27 Танабе Сейяку Ко., Лтд. Производные камптотецина

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2461995A1 (fr) * 1979-07-20 1981-02-06 Lcc Cice Cie Europ Compo Elect Transducteur magneto-electrique pour systeme d'enregistrement magnetique, et systeme d'enregistrement comportant un tel transducteur
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6054386A (ja) * 1983-09-02 1985-03-28 Yoshitomi Pharmaceut Ind Ltd サフラシン誘導体
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
JP2562162B2 (ja) 1986-06-09 1996-12-11 ユニバーシティ・オブ・イリノイ エクテインアシジン７２９、７４３、７４５、７５９ａ、７５９ｂおよび７７０
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
TR200002921T2 (tr) 1998-04-06 2001-02-21 The Board Of Trustees Of The University Of Illinois Yarı-Sentetik ekteinasidinler
CA2331593C (en) 1998-05-11 2008-08-05 Pharma Mar, S.A. Metabolites of ecteinascidin 743
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
AR035842A1 (es) 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
AU783562B2 (en) 2000-01-19 2005-11-10 Trustees Of Columbia University In The City Of New York, The Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
WO2001077115A1 (en) 2000-04-12 2001-10-18 Pharma Mar, S.A. Antitumoral ecteinascidin derivatives
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU96115394A (ru) * 1995-08-02 1998-12-27 Танабе Сейяку Ко., Лтд. Производные камптотецина
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
E.J.Corey et al. J. Am. Chem. Soc. V.l 18,1996, p.9202-9203. Fukuyma et al. J. Am. Chem. Soc. V.l12,1990, p.3712-3713. *

Also Published As

Publication number Publication date
CZ20014102A3 (cs) 2002-06-12
DE60016209D1 (de) 2004-12-30
MXPA01011631A (es) 2002-07-30
AU5649601A (en) 2001-11-26
BRPI0110801B8 (pt) 2021-05-25
PT1185536E (pt) 2005-04-29
NO20025186L (no) 2003-01-14
CZ20023746A3 (cs) 2003-04-16
SI1185536T1 (en) 2005-06-30
BG65896B1 (bg) 2010-04-30
CN1440414A (zh) 2003-09-03
ES2231486T3 (es) 2005-05-16
CN1229382C (zh) 2005-11-30
CN1441805A (zh) 2003-09-10
BRPI0110801B1 (pt) 2018-02-27
US7241892B1 (en) 2007-07-10
WO2001087894A1 (en) 2001-11-22
JP2002544280A (ja) 2002-12-24
BR0110443A (pt) 2003-04-08
HK1047432A1 (en) 2003-02-21
CZ304966B6 (cs) 2015-02-18
DK1185536T3 (da) 2005-04-04
UA75333C2 (uk) 2006-04-17
US20040002602A1 (en) 2004-01-01
RU2237063C2 (ru) 2004-09-27
US20080045713A1 (en) 2008-02-21
BRPI0110443B8 (pt) 2021-05-25
MY130271A (en) 2007-06-29
BR0110801A (pt) 2003-02-11
BR0010559A (pt) 2002-07-02
CZ304973B6 (cs) 2015-02-25
HU230646B1 (hu) 2017-05-29
NO20025186D0 (no) 2002-10-29
HUP0201188A2 (en) 2002-07-29
SK287835B6 (sk) 2011-12-05
CN100475822C (zh) 2009-04-08
DE60016209T2 (de) 2005-12-15
CA2372058C (en) 2010-10-26
NO20015547D0 (no) 2001-11-13
WO2000069862A3 (en) 2001-03-22
NO20015547L (no) 2002-01-14
KR20020021636A (ko) 2002-03-21
NZ515424A (en) 2004-06-25
US7524956B2 (en) 2009-04-28
JP4445136B2 (ja) 2010-04-07
AU775580B2 (en) 2004-08-05
ATE283273T1 (de) 2004-12-15
ES2233367T3 (es) 2005-06-16
CY1108095T1 (el) 2014-02-12
TR200103273T2 (tr) 2002-04-22
AR035842A1 (es) 2004-07-21
CN1211386C (zh) 2005-07-20
CA2406095C (en) 2010-02-16
EP1185536B1 (en) 2004-11-24
CZ20023751A3 (en) 2004-05-12
BG107301A (bg) 2003-07-31
SK16502001A3 (sk) 2002-06-04
CA2372058A1 (en) 2000-11-23
CN1360588A (zh) 2002-07-24
CZ303536B6 (cs) 2012-11-21
BRPI0110443B1 (pt) 2018-06-26
SK287879B6 (sk) 2012-02-03
NO328301B1 (no) 2010-01-25
BRPI0010559B8 (pt) 2021-05-25
EP1185536A2 (en) 2002-03-13
BRPI0010559B1 (pt) 2016-08-30
SI1287004T1 (sl) 2005-12-31
NO322016B1 (no) 2006-08-07
PL353002A1 (en) 2003-09-22
AU4597300A (en) 2000-12-05
WO2001087895A1 (en) 2001-11-22
PL226890B1 (pl) 2017-09-29
SK15272002A3 (sk) 2003-06-03
WO2000069862A2 (en) 2000-11-23
CA2406095A1 (en) 2001-11-22
KR100834601B1 (ko) 2008-06-02

Similar Documents

Publication Publication Date Title
RU2237063C9 (ru) Полусинтетический способ и новые соединения
US7410969B2 (en) Antitumoral analogs of ET-743
US7420051B2 (en) Synthetic process for the manufacture of an ecteinaschidin compound
EP1287004B1 (en) Synthetic process for the manufacture of an ecteinascidin compound
AU2001256496A1 (en) Synthetic process for the manufacture of an ecteinascidin compound
BG106216A (bg) Полусинтетичен метод и нови съединения
HK1050193B (en) Synthetic process for the manufacture of an ecteinascidin compound
NZ521808A (en) Synthetic process for the manufacture of an ecteinaschidin compound

Legal Events

Date Code Title Description
TH4A Reissue of patent specification